Newsroom

Fresenius Kabi announces ustekinumab biosimilar Otulfi® (ustekinumab-aauz) developed by Formycon AG, is now available in the United States

Angels for Change (A4C) announces the pilot launch of Project GOLD (Generic Oncology Lifesaving Drugs), a new resiliency program that establishes an onshore buffer supply of six essential medications that are used to treat cancer.

Fresenius Kabi, an operating company of Fresenius, announced today it has introduced Calcitonin Salmon Injection, USP Synthetic, a calcium regulator, for the treatment of symptomatic Paget’s disease of the bone and hypercalcemia.

Presented to individuals who have made significant strides in advocating for and securing access to essential medicines for patients, driving meaningful change in the race to end drug shortages.

Fresenius Kabi, an operating company of Fresenius, specializing in lifesaving medicines and technologies, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Adaptive Nomogram - an alternate algorithm that will be available in the Aurora Xi Plasmapheresis System - designed to optimize plasma collection efficiency.

Fresenius Kabi, an operating company of Fresenius, announced today that Epinephrine Injection, USP, is now available in the United States as the first generic version of Epinephrine in a 1mg/1mL vial for U.S. customers.

Ori Biotech Ltd., a leader in cell and gene therapy manufacturing technology, and Fresenius Kabi, an operating company of Fresenius, today announced a collaboration to integrate the IRO® platform with Fresenius Kabi’s upstream and downstream processing technologies.

Fresenius Kabi, an operating company of Fresenius, announced today that it has submitted a 510(k) notification to the U.S. Food and Drug Administration seeking clearance of the Aurora Xi Plasmapheresis System software version 2.0.

Fresenius Kabi, an operating company of Fresenius, received a Novaplus Program Excellence Award from Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company. The recognition was announced at the Vizient Connections Summit in Las Vegas.

Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code and granted pass-through payment status for Tyenne® (tocilizumab-aazg).

Fresenius Kabi, an operating company of Fresenius, today named 12 new inductees into the National Blood Donation Hall of Fame. Nominated by blood centers across the U.S., the honorees were chosen for their extraordinary commitment to donating blood or for encouraging blood donation.

Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announces today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies (CGTs).

Fresenius Kabi, an operating company of Fresenius, specializing in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic conditions, and Formycon AG, a leading, independent developer of high-quality biosimilars, announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved OtulfiTM (ustekinumab-aauz), its ustekinumab biosimilar referencing Stelara® ** (ustekinumab). OtulfiTM is approved for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis. Fresenius Kabi is further continuing its momentum, striving at expanding its strong Biopharma platform, which is a substantial cornerstone of #FutureFresenius.

Fresenius Kabi and AABB Announce Start of 19th Annual Blood Collectors Week, September 1-7, 2024. Honoring blood collection professionals and their life-saving impact on patient care

Fresenius Kabi announced today it has launched Cetrorelix Acetate for Injection kit, an FDA-approved, cost-effective, generic option for women’s reproductive health. Cetrorelix Acetate for Injection is available immediately from Fresenius Kabi in a kit that contains one single-dose vial (0.25 mg cetrorelix), one pre-filled syringe with 1 mL sterile water for injection, one 20-gauge needle, and one 27-gauge needle.

Fresenius Kabi, an operating company of Fresenius, has received the 2024 Trailblazer Award from Premier Inc., a leading technology-driven health care improvement company. Premier members comprise approximately 4,350 U.S. hospitals, health systems and more than 300,000 other providers and organizations in health care.

Fresenius Kabi announced today that Arunesh Verma has joined the company as president of Fresenius Kabi USA and a member of the company’s global Executive Leadership Team, reporting to Pierluigi Antonelli, CEO of Fresenius Kabi.

Fresenius, via its operating company Fresenius Kabi, announced today the immediate availability in the U.S. of its biosimilar Tyenne® (tocilizumab-aazg), in a subcutaneous formulation, which will increase access to affordable and cost-effective treatment options for use in the treatment in chronic autoimmune diseases.

Angels for Change, a global non-profit on a mission to end drug shortages, presented the organization’s 2024 Drug Shortage Guardian Award to Fresenius Kabi USA, a health care company that specializes in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition.

Fresenius, via its operating company Fresenius Kabi, announced today the immediate U.S. availability of Tyenne® (tocilizumab-aazg), a biosimilar of Actemra® (tocilizumab). Tyenne®, for use in the treatment of chronic autoimmune diseases, is available in an intravenous (IV) formulation.

Fresenius Kabi, a global health care company that specializes in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic conditions, announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Tyenne®* (tocilizumab-aazg), its tocilizumab biosimilar referencing Actemra®** (tocilizumab). Tyenne® becomes the first tocilizumab biosimilar with both IV and subcutaneous formulations approved by the FDA. In accordance with its patent settlement agreement with Genentech, Fresenius Kabi has a license to market its tocilizumab products in the U.S. commencing on the license dates, which are confidential.

Fresenius Kabi announced today it has introduced Cyclophosphamide for Injection, USP, a generic substitute for Cytoxan, for use in treating several forms of cancer. Now available in the U.S., Cyclophosphamide for Injection, USP is the newest addition to Fresenius Kabi’s broad portfolio of generic oncology injectables that help make cancer therapies more affordable and accessible.

Fresenius Kabi announced today it has introduced Posaconazole Injection, a generic substitute for Noxafil®, for use in treating or preventing serious fungal infections in adults and children who have an increased chance of getting these infections due to a weakened immune system. Now available in the U.S., Posaconazole Injection is the newest addition to Fresenius Kabi’s portfolio of more than 30 anti-infective molecules.

Fresenius Kabi announced today it has signed a multiyear agreement under which the Mayo Clinic is expected to purchase 10,000 Ivenix® large-volume infusion pumps for its hospitals and clinics in Minnesota, Arizona and Florida.

Fresenius Kabi marked the 25th anniversary of its partnership with blood donation centers by naming the 12 newest inductees into the Fresenius Kabi National Blood Donation Hall of Fame. The latest honorees were nominated by blood centers across the United States for their exemplary commitment to donating blood and/or encouraging blood donation.

Fresenius Kabi announced today it has introduced +RFID smart labels for Diprivan® (Propofol) Injectable Emulsion, USP, 200 mg per 20 mL in single-dose vials, sold in the United States. The +RFID labels are now fully compatible with all major RFID kit and tray systems in the U.S.

Fresenius Kabi has been named the 2023 Supplier Partner of the Year by Vizient, Inc., the nation’s largest provider-driven health care performance improvement company. The recognition was celebrated September 18-21 at the 2023 Vizient Connections Summit in Las Vegas.

Fresenius Kabi has been selected to exhibit its Ivenix Infusion System at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest provider-driven healthcare performance improvement company, will hold the Exchange on Oct. 3 in Grapevine, Texas.

Fresenius Kabi announced today it has signed an agreement with Virginia Oncology Associates (VOA) under which VOA will purchase the Ivenix Infusion System to deliver medications for its patients. VOA specializes in treating people with cancer and blood disorders by providing access to innovative therapies and technologies.

Fresenius Kabi and AABB proudly announce the dates of the 18th annual Blood Collectors Week, which runs September 3-9, 2023. Throughout the week, dedicated individuals who make blood collection possible, including phlebotomists, apheresis operators, medical directors, donor recruiters, technicians, and drivers, are honored for their vital role as the connection between blood donors and patients relying on blood for medical conditions.

Fresenius Kabi and Lupagen Inc. announced today the companies have entered into a development and supply agreement for technologies designed to bring the delivery of cell and gene therapies to the bedside.

Fresenius Kabi announced today it has introduced Plerixafor Injection, a generic equivalent to Mozobil®, available immediately in the United States in a 24 mg per 1.2 mL single dose vial.

Fresenius Kabi announced today it has launched Gadobutrol Injection, a generic substitute for the contrast agent Gadavist®, which is used in magnetic resonance imaging (MRI) procedures.

In the wake of the tornado damage to a Pfizer injectables plant in North Carolina on Wednesday July 19, 2023, Fresenius Kabi activated its emergency response team and is in contact with the U.S. Food and Drug Administration’s Drug Shortage Staff (DSS) to help prevent and mitigate potential disruptions to the supply chain of essential medicines. We have also offered assistance to Pfizer, and we wish them and their employees a smooth and safe recovery of their operations.

Fresenius Kabi announced today the launch and immediate availability in the U.S. of Fentanyl Citrate Injection, USP in 100 mcg per 2 mL Simplist® ready-to-administer prefilled syringes, the only 100 mcg per 2 mL presentation available on the market in a manufacturer-prepared prefilled syringe.

Fresenius Kabi announced today it has launched Ganirelix Acetate Injection, a generic fertility drug, as part of the company’s expansion in women’s health. Ganirelix Acetate Injection is available immediately from Fresenius Kabi in 250 mcg/0.5 mL prefilled syringes.

Fresenius Kabi announced today the immediate availability in the U.S. of its citrate-free adalimumab biosimilar IDACIO® (adalimumab-aacf) for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira® (adalimumab). IDACIO is available in a self-administered prefilled syringe and a self-administered pre-filled pen (autoinjector).

Fresenius Kabi announced today that its Ivenix® Infusion System has been selected by the Metrodora Institute to meet the Institute’s infusion medicine needs. The Metrodora Institute is an integrated, multidisciplinary medical and research center dedicated to treating neuroimmune axis disorders.

Fresenius Kabi, a leading provider of injectable medicines, announced today it has launched the diagnostic pharmaceutical agent, Sincalide for Injection, an authorized generic for Bracco Diagnostics Inc.’s Kinevac® (Sincalide for Injection) product. The new product broadens Fresenius Kabi’s radiology portfolio and is available immediately in the United States.

Fresenius Kabi announced today the availability in the United States of Vasopressin Injection, USP, a generic equivalent to Vasostrict®. Fresenius Kabi Vasopressin Injection, USP is an approved treatment option for adults with vasodilatory shock and is available in a 20 Units per 1 mL Single Dose Vial.

Fresenius Kabi announced today the launch and immediate availability in the U.S. of Diazepam Injection, USP in 10 mg per 2 mL Simplist® ready-to-administer prefilled syringes.

Fresenius Kabi, a leading provider of injectable medications, announced today it has launched Rocuronium Bromide Injection with advanced RFID-enabled labels in the United States. Rocuronium Bromide Injection is part of Fresenius Kabi's +RFID™ portfolio of smart-labeled medications, designed to help enhance patient safety and support a more-efficient medication inventory process. This will mark the first +RFID product that is compatible with Bluesight’s KitCheck product, the leading kit and tray solution for American hospitals allowing +RFID products to be used across all major RFID kit and tray vendors.

Fresenius Kabi announced today it has been awarded a Breakthrough Technology group purchasing agreement with Premier, Inc. Effective May 1, 2023, the new agreement allows Premier members, at their discretion, to benefit from special pricing and terms pre-negotiated by Premier for the Ivenix Infusion System from Fresenius Kabi.

Fresenius Kabi announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent product-specific Q-code for Stimufend® (pegfilgrastim-fpgk). Under the Healthcare Common Procedure Coding System (HCPCS), the Q-code assigned to Stimufend is effective for patients administered Stimufend on and after April 1, 2023. The KABICARE™ patient services hub is available to facilitate successful access and reimbursement.

Fresenius Kabi announced today its Ivenix Infusion System has received an Innovative Technology contract from Vizient, Inc. the nation's largest member-driven health care performance improvement company. Vizient members include more than half of all acute care hospitals in the United States, including 97 percent of U.S. academic medical centers.

Fresenius Kabi announced today the immediate availability in the U.S. of Stimufend® (pegfilgrastim-fpgk), the company’s biosimilar to Neulasta® (pegfilgrastim), for use in patients at risk for febrile neutropenia, a common side effect of many anti-cancer medications. Stimufend is available in a single-dose, pre-filled syringe that delivers 6mg/0.6mL solution for subcutaneous injection.

Fresenius Kabi announced today that its Ivenix Infusion System has been successfully implemented at San Luis Valley Health in Colorado.

Fresenius Kabi announced today the immediate availability in the U.S. of Lacosamide Injection, USP, a generic equivalent to VIMPAT®. Fresenius Kabi Lacosamide Injection, USP is an approved treatment option for partial-onset seizures in patients 17 years of age and older and is available in 200 mg per 20 mL single-dose vials.

Fresenius Kabi, a global health care company that specializes in pharmaceuticals, medical technologies, and nutrition products for critical and chronic conditions, announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved its citrate-free adalimumab biosimilar Idacio®* for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira®** (adalimumab).

Fresenius Kabi announced today it has introduced Pralatrexate Injection, a generic equivalent to Folotyn®, for the treatment of relapsed or refractory peripheral T-cell lymphoma. Fresenius Kabi Pralatrexate Injection is available immediately in the United States and is the newest addition to the company’s injectable oncology medicine portfolio, the largest in U.S. health care.

Fresenius Kabi announced today it has introduced KabiCare Nutrition Resources in the United States as part of its KabiCare patient support program. The KabiCare Nutrition Resources program provides support for insurance reimbursement questions including a helpline staffed by experts to provide billing and coding support, insurance support such as benefit investigation, prior authorization and claims appeals.

Fresenius Kabi today announced the 12 newest inductees into the Fresenius Kabi Blood Donation Hall of Fame. For 24 years, the Hall of Fame has recognized and shared the unique stories of those who are passionate about and committed to blood donation.

Fresenius Kabi announced today the successful smart pump interoperability of its Ivenix Infusion System at Fort HealthCare, a regional health care provider in Wisconsin.

Fresenius Kabi has been named the 2022 Pharmaceutical Supplier Partner of the Year by Vizient, Inc., the nation’s largest member-driven health care performance improvement company. The recognition was September 19-21 at the 2022 Vizient Connections Summit in Las Vegas.

resenius Kabi announced today it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent Dotarem®. This is the second contrast agent introduced by Fresenius Kabi in the United States this year. Fresenius Kabi introduced Iodixanol Injection, USP in July during a nationwide shortage.

Fresenius Kabi has been selected to exhibit the Ivenix Infusion System at the Vizient Innovative Technology Exchange. Vizient, Inc, the nation’s largest member-driven health care performance improvement company, will hold the Exchange on October 17, 2022, in Dallas.

Fresenius Kabi, a global health care company that specializes in pharmaceuticals, medical technologies, and nutrition products for critical and chronic conditions, announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved its biosimilar, Stimufend® (pegfilgrastim-fpgk), for use in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. The company expects to launch the product in a prefilled syringe early next year and in an on-body injector following FDA approval.

Fresenius Kabi and AABB announced today the official start of the 17th annual Blood Collectors Week celebration, which runs September 4-10, 2022.

Fresenius Kabi announced today the introduction of a three-year plan to add GS1 Data Matrix barcodes to its pharmaceutical portfolio of vials, syringes, IV solutions and parenteral nutrition products at the unit of use.

Fresenius Kabi, a global healthcare company that specializes in pharmaceuticals, medical technologies and clinical nutrition products for critical and chronic conditions, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s 351(k) Biologics License Application (BLA) for MSB11456, the company’s biosimilar candidate for Actemra®*(tocilizumab).

Fresenius Kabi announced today it has introduced Thiotepa for Injection, USP, in the United States. Thiotepa, a generic equivalent to Tepadina®, is the newest addition to the company’s injectable oncology portfolio – the most comprehensive in the industry.

Fresenius Kabi announced today the immediate availability in the U.S. of Glycopyrrolate Injection, USP in 0.6 mg per 3 mL Simplist® ready-to-administer prefilled syringes.

Fresenius Kabi announced today it will introduce a portfolio of generic contrast media agents in the United States, starting immediately with the launch of Iodixanol Injection, USP, a product the U.S. Food and Drug Administration (FDA) lists as being in shortage nationwide.

Fresenius Kabi announced today the immediate availability in the United States of Romidepsin for Injection, the newest addition to the company’s broad portfolio of injectable oncology medicines.

Fresenius Kabi announced today that its growing +RFID™ portfolio of radio frequency tagged medications is now compatible with AmerisourceBergen’s medication tray solution. AmerisourceBergen is a global health care company and one of the largest pharmaceutical distributors in the United States.

Fresenius Kabi announced today the immediate availability in the U.S. of PEMEtrexed for Injection, USP, a new generic equivalent to Alimta®. Fresenius Kabi produces its PEMEtrexed for Injection, USP in the United States, where the company offers the most comprehensive injectable oncology portfolio of any pharmaceutical manufacturer.

Fresenius Kabi announced today that Brandee Pappalardo, Ph.D., M.P.H. has joined the company as senior vice president and Chief Medical Officer for North America. Dr. Pappalardo reports to John Ducker, president and CEO of Fresenius Kabi in North America and is a member of the company’s North America executive committee.

Following the announced closing of the acquisition of Ivenix and its advanced infusion pump technology, Fresenius Kabi now offers health care professionals in the United States a broad and expanding portfolio of advanced infusion pumps and solutions to meet needs across the continuum of care.

Fresenius Kabi announced today it has introduced Bortezomib for Injection, a new generic equivalent to Velcade® in the U.S. and the newest addition to the most comprehensive injectable oncology portfolio in the industry.

Fresenius Kabi announced today it has introduced two new presentations of Calcium Gluconate in Sodium Chloride Injection in the United States in the company’s proprietary, ready-to-administer freeflex® containers.

Fresenius Kabi announced today it has introduced KabiConnect, part of the KabiCare patient support program in the United States, to offer copay assistance for the company’s generic oncology medicines. Fresenius Kabi offers the most comprehensive portfolio of generic injectable oncology medicines in the U.S.

First steps in executing Fresenius Kabi’s “Vision 2026” growth strategy

resenius Kabi announced today it has been granted an expanded indication for SMOFlipid® Lipid Injectable Emulsion (ILE) for pediatric patients in the United States, including term and preterm neonates, making it the first and only four-oil lipid emulsion for parenteral nutrition patients of every age.

Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today it has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for its wireless Agilia® Connect Infusion System which includes the Agilia® Volumetric Pump and the Agilia® Syringe Pump with Vigilant® Software Suite-Vigilant® Master Med technology. The Agilia Connect volumetric pump and syringe pump are the first to be cleared by following TIR101 standards, which were developed by the Association for the Advancement of Medical Instrumentation (AAMI) in 2021.

Fresenius Kabi USA is voluntarily recalling seven lots of Sodium Acetate Injection, USP, 400 mEq/100 mL (4 mEq/mL), 100 mL fill in a 100 mL vial to the user level due to the presence of particulate matter found in reserve and/or stability sample vials.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for health systems and pharmacies, and Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition, are collaborating to provide U.S. hospitals and health systems with innovative new pharmacy technology designed to support safety and efficiency in dispensing of controlled substances in patient care areas.

Fresenius Kabi announced today it inducted 12 people and groups as the 2021 class of the Fresenius Kabi Blood Donation Hall of Fame. The nationwide program recognizes and shares the unique stories of people who are passionate about and committed to blood donation.

Fresenius Kabi USA, a healthcare company that specializes in life-saving medicines and technologies, and Phlow Corp. (Phlow), a public benefit essential medicines solutions provider, today announced an alliance to reliably supply high-quality essential medicines utilizing advanced manufacturing processes based in the USA.

The Axia Institute of Michigan State University announced the creation of Axia Lab™, a premier research and consulting service leading the way in radio frequency identification (RFID) tagged item assessments, testing, compliance, and technical implementations. Axia Lab provides a neutral environment to facilitate impartial testing of the performance of RFID-tagged items according to GS1 Standards.

Fresenius Kabi and Health Care Logistics®, Inc. (HCL) today announced a collaboration designed to make drug replenishment in hospitals more efficient and improve patient safety throughout the medication-use process. The new collaboration allows customers to utilize Fresenius Kabi’s +RFID™ smart-labeled medications with HCL’s Stat Stock® inventory control solution.

Fresenius Kabi, a global healthcare company that specializes in lifesaving medicines and technologies, announced today that its tocilizumab biosimilar candidate MSB11456 successfully met its primary and secondary endpoints in two consecutively conducted clinical trials. The two Phase 1 studies used respectively subcutaneous and intravenous formulations to capture the two different routes of administration to evaluate the tocilizumab biosimilar candidate’s bioequivalence, safety and immunogenicity, in comparison to its reference candidates.

Fresenius Kabi and AABB announced that today begins the celebration of the 16th annual Blood Collectors Week (Sunday, September 5 through Saturday, September 11, 2021).

Fresenius Kabi announced today the U.S. introduction of Fentanyl Citrate Injection, USP 50 mcg per 1 mL in its proprietary Simplist® ready-to-administer prefilled syringe, the only 1 mL presentation available in the U.S. today.

Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today it has received a 2021 Supplier Legacy Award from Premier Inc. (www.premierinc.com), a leading health care improvement company.

The ASHP Foundation today announced the appointment of Lindsey Thomas and Ellen Wetterling to the ASHP Foundation Board of Directors as directors at large.

Fresenius Kabi announced today the immediate availability of Temsirolimus Injection in the United States. Fresenius Kabi’s Temsirolimus Injection is supplied as a kit including one vial of 25 mg/mL Temsirolimus solution and one vial of diluent.

Fresenius Kabi announced today it has introduced in the United States two new presentations of Heparin Sodium in convenient, ready-to-administer Freeflex® IV bags.

Fresenius Kabi, a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition, today announced it has signed an exclusive distribution agreement for the U.S. with Corvida Medical.

Fresenius Kabi announced today the immediate availability in the United States of Foscarnet Sodium Injection. Fresenius Kabi Foscarnet Sodium Injection is available in 6000 mg / 250 mL bottle.

Fresenius Kabi USA is voluntarily recalling a single lot of Ketorolac Tromethamine Injection, USP, 30 mg/mL, 1 mL fill in a 2 mL amber vial to the user level due to the presence of particulate matter.

Fresenius Kabi announced today the immediate availability in the United States of acetaminophen injection in freeflex® bags.

resenius Kabi and Kit Check today announced the companies have entered into an agreement under which Fresenius Kabi +RFID™ medications will be read by the Kit Check inventory management solution. The collaboration signals both companies’ commitment to medication safety and quality patient care across the health care continuum.

Fresenius Kabi announced today it has introduced icatibant injection in the United States with immediate availability. Icatibant injection is an FDA-approved and cost-effective alternative to treat acute attacks of hereditary angioedema (HAE) in adults.

Fresenius Kabi USA is voluntarily recalling a single lot of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 mcg/50 mL (4 mcg /mL), 50 mL fill in a 50 mL vial. Fresenius Kabi initiated this recall due to a trace amount of lidocaine present in the lot. This recall is being performed to the user level.

Fresenius Kabi announced today it has inducted 13 people and organizations as the 2020 class of the Fresenius Kabi Blood Donation Hall of Fame, a nationwide program that recognizes and shares the unique stories of individuals from across the country who are passionate about and committed to blood donation, by donating themselves, and encouraging others to do so as well.

Fresenius Kabi announced today it has introduced the first in a growing line of medications that come with smart labels embedded with radio-frequency identification technology. The first +RFID™ smart-labeled product, Diprivan® (Propofol) 200 mg per 20 mL (10 mg per mL) Injectable Emulsion, USP, is now available in the United States.

Fresenius Kabi and AABB are celebrating the 15th annual Blood Collectors Week September 6-12, 2020.

Fresenius Kabi announced today it is introducing smart labels for a range of essential medications used in hospitals. The new labels, which feature embedded radio-frequency identification (RFID) technology, will be introduced this year for medications commonly used in the operating room, with the first product launching in September.

Fresenius Kabi USA is voluntarily recalling two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 mcg/50 mL (4 mcg / mL), 50 mL fill in a 50 mL vial. Fresenius Kabi initiated this recall due to the possibility of a trace amount of lidocaine present in these two lots and our investigation indicates that this issue is limited to these two product lots. This recall is being performed to the user level.

Fresenius Kabi announced today the availability in the United States of Simplist® Morphine Sulfate Injection, USP 2 mg per 1 mL and 4 mg per 1 mL ready-to-administer prefilled syringes in MicroVault packaging.

Fresenius Kabi announced today that following the recent U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA), Fresenius Kabi Propoven 2% (propofol 20 mg/mL) Emulsion 100 mL is now available in the U.S. The drug provides sedation via continuous infusion in patients greater than 16 years old who require mechanical ventilation in an intensive care unit (ICU).

Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today the U.S. Food and Drug Administration has accepted for review the company’s Biologics License Application (BLA) for MSB11455, the company’s pegfilgrastim biosimilar candidate for Neulasta®.

Fresenius Kabi announced today the immediate availability in the United States of Micafungin for Injection.

Fresenius Kabi announced today the immediate availability in the United States of Potassium Phosphates Injection, USP in the following presentations: 15 mM per 5 mL, 45 mM per 15 mL and 150 mM per 50 mL.

Fresenius Kabi USA, LLC is voluntarily recalling 13 lots of Ketorolac Tromethamine Injection, USP, 30 mg/mL, 1 mL fill in a 2 mL amber vial and Ketorolac Tromethamine Injection, USP, 60 mg/2 mL (30 mg/mL), 2 mL fill in a 2 mL amber vial to the user level due to the presence of particulate matter composed of the following elements: carbon, silicon, oxygen and polyamides. Particulate matter was found in eight reserve sample vials.

At no time in recent history has the vital role of nurses in America been so clear. To honor nurses on the front lines of the COVID-19 crisis, Kino Lorber is offering a free streaming re-release of the acclaimed documentary, THE AMERICAN NURSE (www.americannurseproject.com)

Fresenius Kabi announced today the availability in the United States of its Glucagon Emergency Kit, an FDA-approved and cost-effective alternative to treat severe hypoglycemic episodes in people with diabetes.

he Centers for Medicare and Medicaid Services (CMS) has assigned an HCPCS Level II code to Omegaven®, the newest parenteral nutrition product introduced in the United States by Fresenius Kabi.

Bio-Techne, Fresenius Kabi, and Wilson Wolf have formed a new joint venture company to provide dedicated support to researchers and biopharmaceutical companies in the field of cell and gene therapy.

Fresenius Kabi announced today the immediate availability in the United States of Dicyclomine Hydrochloride Injection, USP in 20 mg per 2 mL single-dose vial.

Fresenius Kabi announced today the availability in the United States of Ertapenem for Injection in a 1 gram vial presentation. The new product is the generic equivalent to Invanz®.

The American Society of Anesthesiologists (ASA) announced today that Fresenius Kabi USA will continue its partnership with ASA as an ASA Industry Supporter.

Fresenius Kabi announced today the immediate availability in the United States of Fosaprepitant for Injection 150 mg per vial, the newest addition to the company’s generic oncology portfolio.

Fresenius Kabi announced today the availability in the United States of preservative-free Heparin Sodium Injection, USP in 5,000 USP units per 0.5 mL in Simplist® ready-to-administer prefilled syringes.

Fresenius Kabi announced today it has inducted 15 people into the 2019 Fresenius Kabi Blood Donation Hall of Fame.

Fresenius Kabi announced today the immediate availability in the United States of Fulvestrant Injection 250mg per 5mL prefilled syringe, an expansion of the company’s broad portfolio of injectable oncology medicines.

Fresenius Kabi announced today the immediate availability in the United States of Fulvestrant Injection 250mg per 5mL prefilled syringe, an expansion of the company’s broad portfolio of injectable oncology medicines.

Fresenius Kabi and AABB are celebrating the 14th annual Blood Collectors Week September 1-7, 2019.

Fresenius Kabi announced today the immediate availability in the United States of Phenylephrine Hydrochloride Injection, USP.

Fresenius Kabi, a global health care company, is establishing a regional distribution center in Pleasant Prairie. The multimillion-dollar investment is expected to create 95 jobs over the next four years.

Fresenius Kabi announced today the immediate availability in the United States of Levothyroxine Sodium Injection Solution in 100 mcg per 5 mL, 200 mcg per 5 mL and 500 mcg per 5 mL single-dose vials.

Fresenius Kabi announced today the immediate availability in the United States of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a medication for sedation of non-intubated patients prior to and/or during surgical and other procedures.

Fresenius Kabi announced today the immediate availability in the United States of Neostigmine Methylsulfate Injection, USP in 3 mg per 3 mL Simplist® ready-to-administer prefilled syringes

ProvideGx, LLC, a consolidated subsidiary of Premier Inc. (NASDAQ: PINC) and a healthcare improvement company developing a more stable and reliable supply chain for generic drugs in short supply, is collaborating with Fresenius Kabi to help mitigate national shortages of injectable thiamine, lidocaine, diphenhydramine, hydromorphone and morphine sulfate.

Fresenius Kabi announced today the immediate availability in the United States of Glycopyrrolate Injection, USP in 0.2 mg per 1 mL and 0.4 mg per 2 mL single dose in Simplist® ready-to-administer prefilled syringes.

Fresenius Kabi announced today the immediate availability in the United States of Adenosine Injection, USP in 6 mg per 2 mL and 12 mg per 4 mL single dose in Simplist® ready-to-administer prefilled syringes.

Fresenius Kabi today announced it has received 510(k) clearance from the U.S. Food and Drug Administration for the Fenwal Amicus® Red Blood Cell Exchange (RBCx) system.

Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today the immediate availability in the United States of Methocarbamol Injection, USP in a 100 mg per mL 10 mL vial presentation.

Fresenius Kabi announced today the immediate availability in the United States of Leucovorin Calcium Injection, USP, a medication indicated to counteract the toxicity and diminish the effects of impaired methotrexate elimination.

Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today that Omegaven® (fish oil triglycerides) injectable emulsion is now commercially available in the United States. This novel lipid had previously been available only for compassionate use in the U.S.

Fresenius Kabi announced today it has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration (FDA).

Fresenius Kabi USA is voluntarily recalling 163 lots of Sodium Chloride Injection, USP, 0.9%, 10 mL fill in a 10 mL vial and Sodium Chloride Injection, USP, 0.9%, 20 mL fill in a 20 mL vial to the user level.

Fresenius Kabi announced today the immediate availability in the United States of Arsenic Trioxide Injection in a 10 mg per 10 mL vial presentation.

Fresenius Kabi announced today the immediate availability in the United States of the Simplist® Palonosetron Hydrochloride Injection. The Simplist® Palonosetron Hydrochloride Injection is available in a 0.25 mg per 5 mL single dose ready-to-administer prefilled syringe.

Fresenius Kabi announced today it has introduced four new presentations of Heparin Sodium in the company’s proprietary ready-to-administer freeflex® containers.

Fresenius Kabi announced today the immediate availability in the United States of Atropine Sulfate Injection, USP in an 8 mg per 20 mL presentation.

Fresenius Kabi announced today the immediate availability in the United States of Glycopyrrolate Injection, USP in 0.2 mg per mL, 0.4 mg per 2 mL, 1 mg per 5 mL and 4 mg per 20 mL presentations.

Today, the Association for Accessible Medicines (AAM) released its “Generic Access and Savings Report in the United States 2018,” which finds that 93 percent of generic prescriptions are filled at $20 or less, and that the average co-pay for a generic drug is just $6.06.

Fresenius Kabi announced today the immediate availability in the United States of Adenosine Injection, USP in 60 mg per 20 mL and 90 mg per 30 mL presentations.

Fresenius Kabi announced today the immediate availability in the United States of Melphalan Hydrochloride for Injection. Fresenius Kabi Melphalan Hydrochloride for Injection is available as a two-vial kit containing one single dose vial of Melphalan Hydrochloride equivalent to 50 mg Melphalan and one vial of sterile diluent.

Fresenius Kabi announced today it has received FDA approval for Daptomycin for Injection and the product is available immediately for customers in the United States. Daptomycin for Injection is an antibiotic and a generic alternative to CUBICIN®.

Fresenius Kabi announced today the immediate availability in the United States of Palonosetron Hydrochloride Injection.

Fresenius Kabi announced today the immediate availability in the United States of Remifentanil Hydrochloride for Injection.

The American Society for Parenteral and Enteral Nutrition (ASPEN) and Fresenius Kabi announced today a new educational video series highlighting best practices for dosing, preparing and administering intravenous lipid emulsions (ILE).

Fresenius Kabi announced today the availability in the United States of Bortezomib for Injection. Fresenius Kabi Bortezomib for Injection is available as a single dose vial containing 3.5 mg of lyophilized powder.